Back to Agendas
Session 8: Hot Topics
Session Chair(s)
Arthur A. Levin, PHD
Distinguished Scientist
Avidity Biosciences, United States
Emily Place, PHD, MPH
Senior Consultant
Aclairo Pharmaceutical Development Group, United States
There are numerous ways the oligonucleotides have been used for the treatment of disease. The most prominent ones have worked via RNAase H, splice switching, siRNA, apatmer, and immuinomodulaor mechanisms. There are many more potential ways to apply oligonucleotides as therapeutic agents. This session will explore two additional mechanisms, U1 Adaptor Oligonucleotides, and the CRISPR cas. The evolution of novel technologies will undoubtedly influence the field moving forward.
Speaker(s)
Development of U1 Adaptor Gene Silencing Oligonucleotide Therapeutics
Sam Gunderson
Rutgers University, United States
Associate Professor
Advancing the CRISPR/Cas9 Technology Platform for Therapeutics Applications
Alexandra Glucksmann, PHD
Editas Medicine, United States
Chief Operating Officer
Q&A Panel Discussion
United States
Have an account?